Posted inCardiology Nephrology news
Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with chronic kidney disease and elevated lipoprotein(a).